Ema evaluates Pfizer-BioNTech vaccines for 12-15 year olds
Vaccines, a quarter of Italians received the first dose.
Federnuoto hub inaugurated
Vaccines, between 5 and 7 May 2.1 million Pfizer doses in Italy
Share
04 May 2021
The EMA has started the examination (in 'rolling review') of the vaccine developed by the Chinese Sinovac.
This was announced by the European Agency on Twitter.
The EMA has started the examination of the inactivated serum - Vero cell - developed by Sinovac Life Sciences Co. The EU applicant is Life 'On Srl It is specified in the note.
The decision is based on preliminary results from laboratory and clinical studies that suggest that the vaccine triggers the production of antibodies that target Sars-CoV-2, the virus that causes Covid-19, and may help protect against the disease.
The EMA will evaluate the data as it becomes available to decide whether the benefits outweigh the risks. The analysis will continue until sufficient evidence is available for a formal marketing authorization application.